What To Expect From Kroger (KR) Q2 Earnings After Target, Walmart Impress
Zacks Investment Research | Aug 29, 2019 07:41AM ET
Shares of Kroger (NYSE:KR) have tumbled 14% in 2019, in dramatic contrast to its industry’s 16% climb and the S&P 500’s roughly 14% jump. The recent downturn continues the grocery’s giants dismal run over the last three-plus years.
Kroger has, however, flashed signs of life as it tries to revamp some of its business and roll out more delivery and e-commerce offerings. On top of that, second-quarter earnings season has seen retail powers Walmart (NYSE:WMT) and Target (NYSE:TGT) prove once again to Wall Street that their growth initiatives have paid off.
Kroger Overview
Kroger is the country’s largerest supermarket operator and its recent woes tell an all too familiar story in the Amazon (NASDAQ:AMZN) -obsessed retail age. The Cincinnati, Ohio-based firm faces increased competition from its aforementioned rivals, Walmart, Target, and Amazon, which have all pushed deeper into the grocery industry and attracted consumers to their delivery and pick-up options.
With that said, Kroger’s e-commerce investments have started to prove somewhat valuable. The company’s digital sales soared 42% in the first quarter of 2019 and management noted that home-delivery offerings or pickup were available at 93% of its locations—1,685 pickup locations and 2,126 delivery locations. Like some of its peers, Kroger has also beefed up its own brands. Last quarter, Kroger’s brand sales climbed 3.3%, with double-digit growth in Simple Truth.
Meanwhile, Kroger invested a combined total of $589 million in meal kit firm Home Chef and Ocado (LON:OCDO), which includes a high-tech fulfillment center. Kroger also has a partnership with Walgreens (NASDAQ:WBA) . Despite all of the positive steps, the company’s same-store sales, excluding fuel, popped 1.5% last quarter, which came in below the year-ago period and short of Wall Street estimates.
Q2 Outlook & Beyond
Looking ahead, Kroger’s Q2 revenue is projected to jump roughly 2% to $28.42 billion, based on our current Zacks Consensus Estimate. The firm’s full-year fiscal 2019 sales are then projected to climb 1.4% to reach $122.88 billion. Peeking further down the road, KR’s 2020 revenue is expected to jump 2.6% above our current year estimate.
Perhaps more importantly, our Key Company Metrics estimates call for the grocery firm’s Q2 comparable sales to jump 1.7%. This would beat the first quarter’s 1.5% growth and come on top of the year-ago period’s 1.6% identical sales expansion.
Get The News You Want
At the bottom end of the income statement, KR’s adjusted quarterly earnings are expected to pop 2.4% to $0.42 per share. Third-quarter EPS is projected to climb 4.2%, with fiscal 2019 earnings expected to jump 2.8%. Similar to the top line, Kroger’s fiscal 2020 earnings are projected to surge 7.3% above our current-year estimate.
Bottom Line
Kroger’s overall earnings estimates have slipped slightly for Q2, as well as fiscal 2019 and 2020 over the last few months. This isn’t a great sign, but Wall Street might be pleased to see that KR’s earnings and revenue are projected to come in significantly higher in 2020 in a sign that its e-commerce and delivery options could pull in more customers.
Kroger is Zacks Rank #3 (Hold) at the moment, but that could change as we get closer to its Q2 earnings release, which is due out on Thursday, September 12. Kroger does sport “A” grades for both Value and Growth in our Style Scores system. Plus, its dividend yield rests at 2.72% at the moment. But investors should note that this is slightly inflated based on its declining stock price.
Breakout Biotech Stocks with Triple-Digit Profit PotentialThe biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.